Claims for Patent: 7,879,819

Summary for Patent: 7,879,819

Title:	Nanoparticles for protein drug delivery
Abstract:	The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one antibiotics or equivalent bioactive agent characterized with a positive surface charge and their enhanced permeability in oral drug delivery.
Inventor(s):	Sung; Hsing-Wen (Hsinchu, TW), Tu; Hosheng (Newport Beach, CA)
Assignee:	GP Medical, Inc. (Newport Beach, CA) National Tsing Hua University (Hsinchu, TW)
Application Number:	12/455,388
Patent Claims:	1. A method of treating diabetes in a subject, comprising administering bioactive nanoparticles to said subject, wherein said bioactive nanoparticles consist of a positively charged chitosan, a negatively charged organic compound, and at least one anti-diabetic drug, wherein a shell portion of said nanoparticles is dominated by said positively charged chitosan, and wherein a core portion of said nanoparticles is formed by electrostatically complexing the positively charged chitosan and said negatively charged. 2. The method of claim 1, wherein the chitosan is N-trimethyl chitosan, EDTA-chitosan, or chitosan derivatives. 3. The method of claim 1, wherein said nanoparticles have a mean particle size between about 50 and 400 nanometers. 4. The method of claim 1, wherein said nanoparticles are loaded in tablets or pills. 5. The method of claim 1, wherein said nanoparticles are encapsulated in a capsule. 6. The method of claim 5, wherein said capsule further comprises a second anti-diabetic drug which is different from said at least one anti-diabetic drug in said bioactive nanoparticles. 7. The method of claim 5, wherein said capsule further comprises at least a solubilizer or a pharmacopocial excipient. 8. The method of claim 5, wherein said capsule further comprises an absorption enhancer. 9. The method of claim 8, wherein said absorption enhancer is selected from the group consisting of Ca.sup.2+ chelators, bile salts, anionic surfactants, medium-chain fatty acids, phosphate esters, chitosan, and chitosan derivatives. 10. The method of claim 1, wherein said nanoparticles are freeze-dried, thereby said nanoparticles being in a powder form. 11. The method of claim 1, wherein said nanoparticles are mixed with trehalose and then freeze-dried, thereby said nanoparticles being in a powder form. 12. The method of claim 1, wherein said nanoparticles further comprise magnesium sulfate or TPP. 13. The method of claim 1, wherein said anti-diabetic drug is insulin or insulin analog. 14. The method of claim 1, wherein said anti-diabetic drug is an insulin sensitizer. 15. The method of claim 1, wherein said anti-diabetic drug is an insulin secretagogue. 16. The method of claim 1, wherein said anti-diabetic drug is a GLP-1 analog. 17. The method of claim 1, wherein said anti-diabetic drug is an inhibitor of dipeptidyl peptidase 4 (DIP-4 inhibitor). 18. The method of claim 1, wherein said anti-diabetic drug is exenatide, liraglutide, albiglutide, or taspoglutide. 19. The method of claim 1, wherein said anti-diabetic drug is selected from the group consisting of alpha-glucosidase inhibitors, amylin analog, sodium-glucose co-transporter type 2 (SGLT2) inhibitors, benfluorex, and tolrestat.

Details for Patent 7,879,819

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Glaxosmithkline Llc	TANZEUM	albiglutide	For Injection	125431	04/15/2014		2025-01-04